These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 2454356)

  • 1. Carvedilol for systemic hypertension.
    Heber ME; Brigden GS; Caruana MP; Lahiri A; Raftery EB
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S113-8. PubMed ID: 2454356
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carvedilol for systemic hypertension.
    Heber ME; Brigden GS; Caruana MP; Lahiri A; Raftery EB
    Am J Cardiol; 1987 Feb; 59(5):400-5. PubMed ID: 2880498
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of low dose carvedilol on circadian variation of blood pressure in patients with essential hypertension.
    Ogihara T; Ikeda M; Goto Y; Yoshinaga K; Kumahara Y; Iimura O; Ishii M; Murakami E; Takeda T; Kokubu T
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S108-12. PubMed ID: 2454355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circadian antihypertensive profile of carvedilol (BM 14190).
    Meyer-Sabellek W; Schulte KL; Distler A; Gotzen R
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S119-23. PubMed ID: 2454357
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Controlled-release carvedilol in the treatment of essential hypertension.
    Weber MA; Sica DA; Tarka EA; Iyengar M; Fleck R; Bakris GL
    Am J Cardiol; 2006 Oct; 98(7A):32L-38L. PubMed ID: 17023230
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Three-dimensional echocardiographic and magnetic resonance assessment of the effect of telmisartan compared with carvedilol on left ventricular mass a multicenter, randomized, longitudinal study.
    Galzerano D; Tammaro P; del Viscovo L; Lama D; Galzerano A; Breglio R; Tuccillo B; Paolisso G; Capogrosso P
    Am J Hypertens; 2005 Dec; 18(12 Pt 1):1563-9. PubMed ID: 16364826
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Resting and postexercise hemodynamic effects of carvedilol, a beta-adrenergic blocker and precapillary vasodilator in hypertensive patients.
    Leonetti G; Sampieri L; Cuspidi C; Boselli L; Terzoli L; Rupoli L; Zanchetti A
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S94-6. PubMed ID: 2454377
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical efficacy of carvedilol in severe hypertension.
    Ogihara T; Yoshinaga K; Kamahara Y; Ikeda M; Goto Y; Arakawa K; Iimura I; Ishii M; Kokubu T; Takeda T
    J Cardiovasc Pharmacol; 1991; 18 Suppl 4():S69-72. PubMed ID: 1721983
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carvedilol in hypertension: effects on hemodynamics and 24-hour blood pressure.
    Lund-Johansen P; Omvik P; Nordrehaug JE; White W
    J Cardiovasc Pharmacol; 1992; 19 Suppl 1():S27-34. PubMed ID: 1378146
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of a new vasodilating beta-blocker, carvedilol, with atenolol in the treatment of mild to moderate essential hypertension.
    Ruilope LM
    Am J Hypertens; 1994 Feb; 7(2):129-36. PubMed ID: 7910028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of carvedilol on ambulatory blood pressure, renal hemodynamics, and cardiac function in essential hypertension.
    Dupont AG; Van der Niepen P; Taeymans Y; Ingels M; Piepsz A; Bossuyt AM; Block P; Six RO; Jonckheer MH; Vanhaelst L
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S130-6. PubMed ID: 2454359
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new molecule with vasodilating and beta-adrenoceptor blocking properties.
    Abshagen U
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S23-32. PubMed ID: 2454364
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic and pharmacodynamic comparison of controlled-release carvedilol and immediate-release carvedilol at steady state in patients with hypertension.
    Henderson LS; Tenero DM; Baidoo CA; Campanile AM; Harter AH; Boyle D; Danoff TM
    Am J Cardiol; 2006 Oct; 98(7A):17L-26L. PubMed ID: 17023228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of carvedilol on blood pressure in patients with mild to moderate hypertension. A dose response study.
    McPhillips JJ; Schwemer GT; Scott DI; Zinny M; Patterson D
    Drugs; 1988; 36 Suppl 6():82-91. PubMed ID: 2908306
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of carvedilol in exercise-induced myocardial ischemia.
    Kaski JC; Rodriguez-Plaza L; Brown J; Maseri A
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S137-40. PubMed ID: 2454360
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy of once-daily carvedilol vs twice-daily labetalol in mild to moderate hypertension.
    Ollivier JP; Durier P; Bussiere JL; Gayet JL
    Eur J Clin Pharmacol; 1990; 38 Suppl 2():S164-6. PubMed ID: 1974509
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antianginal efficacy of carvedilol, a new beta-blocker with vasodilating action.
    Jamal SM; Freedman SB; Thomson A; Carter G; Harris PJ; Kelly DT
    J Cardiovasc Pharmacol; 1987; 10 Suppl 11():S141-6. PubMed ID: 2454361
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of a new vasodilating beta-blocking drug, carvedilol, on left ventricular function in stable angina pectoris.
    Lahiri A; Rodrigues EA; Al-Khawaja I; Raftery EB
    Am J Cardiol; 1987 Apr; 59(8):769-74. PubMed ID: 2881480
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The preventative effects of vasodilating beta-blockers in cardiovascular disease.
    Raftery EB
    Eur Heart J; 1996 Apr; 17 Suppl B():30-8. PubMed ID: 8733069
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.